Beaglehole B

Department of Psychological Medicine, University of Otago, Christchurch, New Zealand.

7 papers · ORCID

ArticleKetamine

Ketamine Dose and Duration Effects in Internalizing Disorders.

McNaughton N, Beaglehole B, Glue P

Europe PMC2026
ArticleKetamine

Ketamine Dosing Across Clinical Indications: A Narrative Review Organized by Proposed NMDA-Related Mechanisms.

Glue P, Beaglehole B

Europe PMC2026
ArticlePsilocybin

Hope for Neurotic Disorders: A Summary of New Zealand Research on the Development of Biomarkers and Novel Treatments.

McNaughton N, Shadli SM, Beaglehole B +1

Europe PMC2026
ArticleKetamine

Ketamine for treatment-resistant post-traumatic stress disorder: double-blind active-controlled randomised crossover study.

Beaglehole B, Glue P, Neehoff S +7

Europe PMC2025
ArticlePsilocybin

Reappraisal of the hype and hope offered by psilocybin treatment of depression.

Beaglehole B, Manuel J

Europe PMC2025
ArticleKetamine

Protocol for a randomised controlled trial of ketamine versus ketamine and behavioural activation therapy for adults with treatment-resistant depression in the community.

Beaglehole B, Porter R, Douglas K +9

Europe PMC2024
ArticleKetamine

Multidisciplinary development of guidelines for ketamine treatment for treatment-resistant major depression disorder for use by adult specialist mental health services in New Zealand.

Beaglehole B, Glue P, Clarke M +1

Europe PMC2023